Biomarker HF risk score envisioned as SGLT2 inhibitor lodestar in diabetes
January 19, 2021
Together, four “easily measured” biomarkers predicted 5-year heart failure risk in patients with diabetes or prediabetes, potentially identifying best candidates for SGLT2 inhibitor therapy, some say.
Calcium burden drives CV risk whether coronary disease is obstructive or not
December 10, 2020
That future cardiovascular risk tracks closely with plaque burden, but not so much with whether the coronary disease is obstructive, may never have been so clearly illustrated.
The socioeconomic revolving door of 30-day heart failure readmissions
October 9, 2020
Racial disparities in 30-day HF readmissions stem partly from variation in economic status of residential neighborhoods, regardless of hospital care quality or insurance coverage, a study suggests.
‘Cautious’ DOAC underdosing in AFib may push mortality higher
September 21, 2020
Risk-averse clinicians might be doing more harm than good by prescribing direct oral anticoagulants at lower-than-recommended dosages in hope of avoiding bleeding complications, suggests a study.
Minidose edoxaban may safely cut AFib stroke risk in the frail, very elderly
September 3, 2020
Those who took the factor Xa inhibitor edoxaban (Savaysa) at the off-label dosage of 15 mg once daily showed a two-thirds drop in risk for stroke or systemic embolism, compared with patients who received placebo.
All NSAIDs raise post-MI risk but some are safer than others: Next chapter
August 5, 2020
A new cohort analysis extends NSAID cautions in high-CV-risk patients to a Korean population. Some question whether the steep climbs in risk seen for some of the drugs are real.
Heart damage even after COVID-19 ‘recovery’ evokes specter of later heart failure
July 31, 2020
Recovery from acute COVID-19 isn’t necessarily the end of it, clearly. Two reports aim to clarify how SARS-CoV-2 can directly invade the heart and indirectly cause persisting myocardial injury.
Dapagliflozin benefits low-EF heart failure regardless of diuretic dose: DAPA-HF
June 26, 2020
The trial that turned an SGLT2 inhibitor into a heart failure drug also has clues to mechanisms behind the observed benefits. Contrary to early speculation, diuresis may be off the list.
Signature STEMI sign may be less diagnostic in the COVID-19 age
April 22, 2020
ST-segment elevation, often a ticket to the cath lab, may not indicate STEMI as reliably as before hospitals started to fill with COVID-19 patients, who may have other ST-segment–elevating conditions.
DAPA-HF: Dapagliflozin benefits regardless of age, HF severity
November 25, 2019
PHILADELPHIA – The SGLT2 inhibitor had similar efficacy in the elderly, and across the spectrum of baseline symptom status.